All In Biotech

Drug Trial Radar · NCT07054606

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

A Phase 4, Multicenter, Open-Label Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

104

Actual

Start

Jul 2, 2025

Primary completion

Nov 3, 2025

Study completion Nov 3, 2025

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assess the impact of concomitant Miebo use while wearing contact lenses

Conditions

  • Dry Eye

Interventions

  • Perfluorohexyloctane ophthalmic solutionDrug

    Eligible subjects will receive Miebo up to 4 times bilaterally on Day 1/Visit 1 (1 drop instilled bilaterally by site staff in-clinic while wearing contact lenses and the rest self-administered throughout the remainder of the day while wearing contact lenses). Starting on Day 2, subjects will self-administer the first drop of Miebo bilaterally before inserting contact lenses for the day. Subjects will wait 30 minutes after the first dose of Miebo to insert their contact lenses and will then instill 3 additional drops of Miebo while wearing contact lenses approximately evenly spaced throughout the rest of the day. Subjects will continue to self-administer Miebo QID bilaterally following the dosing schedule from Day 2 for approximately 30 days. Subjects are expected to record daily VAS assessments throughout the study. The VAS assessments will be collected by the sites at Visits 2, 3, and 4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline (CFB) in CLDEQ-8 score at Visit 4Time frame: Assessed for approximately 30 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site 101

    San Diego, California

  • Site 107

    Longwood, Florida

  • Site 104

    Pittsburg, Kansas

  • Site 102

    Medina, Minnesota

  • Site 108

    Vestal, New York

  • Site 103

    Athens, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.